

Contents

1	The Impact of Preclinical Planning and Study Outcome on the Risk Management of Biologics	1
	<i>By Dan Wierda, PhD, ATS</i>	
2	Risk Management Regulations in the US	11
	<i>By Brande Yaist, Debra Gash, Debashish Dey, MD, PhD, MPH and Nayan Acharya</i>	
3	Regulations Related to Risk Management in Japan.....	35
	<i>By Yong Huang, MD, PhD and Hiroshi Nakane</i>	
4	European Experience With Additional Risk Minimization and Its Impact on Benefit-Risk.....	41
	<i>By Stephen Heaton, Gabriela Wirsching, Suzanne Frankfort, Ursula Maria Schmidt-Ott and Yuhong Wang</i>	
5	Risk Management of Medicines and Biologics in Australia.....	49
	<i>By Judy Bingham, MHSc</i>	
6	Benefit-Risk Management: Current Trends and Future Directions	57
	<i>By Meredith Smith, PhD, MPA</i>	
7	Risk Management in the Medical Device and Food Industries	63
	<i>By Salma Michor, PhD, MBA, CMgr, CQA, RAC</i>	
8	Quality Risk Management (QRM)—A Gateway to Quality by Design (QbD)	71
	<i>By Peter Schiemann, PhD and Beat Widler, PhD</i>	
9	Benefit-Risk Assessment: Art or Science?	79
	<i>By Mariette Boerstool-Streefland, MD, MSc, MBA</i>	
10	Benefit-Risk Evaluation: Latest Regulatory Agency Innovation Activities	85
	<i>By Elaine B. Taylor and Kiley DePolo</i>	
11	Use of Pregnancy Registries for Risk Management.....	95
	<i>By Jessica Albano, Vikki Brown, MD, Angie Graves, Nadja Merkusheva and Roxana Silica</i>	
12	Clinical Evaluation Reports.....	101
	<i>By Evangeline Loh, PhD and Chris Brodrick</i>	
13	Risk Communication: Learning From Experts, Learning From Evidence	107
	<i>By Lee L. Zwaniger, PhD</i>	
14	Postmarketing Pharmacoepidemiology Database Study Development to Evaluate Long-Term Drug Safety—An Example, Prolia....	113
	<i>By Fei Xue</i>	
15	Risk Management in the Future: Looking Into the Crystal Ball.....	119
	<i>By Tjeerd van Staa, MD, MSc</i>	
16	Social Science Theory as a Framework for Designing and Evaluating Pharmaceutical Risk Management Dissemination and Implementation Strategies	125
	<i>By Elaine H. Morrato, DrPH, MPH, CPH</i>	
17	EHR Use for Stimulated Reporting of Adverse Drug Events	139
	<i>By Angela Walker, MD and Richard Loomis, MD</i>	
	Index.....	149
	About the Editors.....	159